Fatty acid ethyl esters: A novel biologic marker for heavy in utero ethanol exposure: A case report

Therapeutic Drug Monitoring

Volumn 21, Issue 6, 1999, Pages 644-646

  Klein, Julia ^a   Karaskov, Tatyana ^a   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarker; Ethanol; Fatty acid ethyl esters; In utero; Meconium

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; FATTY ACID ESTER;

ALCOHOL CONSUMPTION; ARTICLE; BIRTH DEFECT; CASE REPORT; DRUG DETERMINATION; DRUG MONITORING; FETAL ALCOHOL SYNDROME; GAS CHROMATOGRAPHY; HUMAN; MALE; MATERNAL BEHAVIOR; MECONIUM; NEWBORN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

ALCOHOL DRINKING; BIOLOGICAL MARKERS; CHROMATOGRAPHY, GAS; ETHANOL; FATTY ACIDS; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LINOLEIC ACID; LINOLEIC ACIDS; MALE; MATERNAL-FETAL EXCHANGE; MECONIUM; PALMITIC ACID; PREGNANCY; PREGNANCY COMPLICATIONS; STEARIC ACIDS;

EID: 0032699098     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199912000-00011     Document Type: Article

References (14)

1. Abel, EL. An update on incidence of FAS: FAS is not an equal opportunity birth defect. Neurotoxicol Teratol 1995;17:437-43.
2. Institute of Medicine (IOM) of the National Academy of Sciences Committe to Study Fetal Alcohol Syndrome. Summary. Fetal Alcohol Syndrome: Diagnosis, Epidemiology, Prevention and Treatment. In Stratton K, Howe C, Battaglia F, eds. Fetal Alcohol Syndrome. Washington, D.C.: National Academy Press, 1996, 57.
3. Koren G, and Nulman I. Teratogenic drugs and chemicals in humans. In: Koren G, ed. Maternal-Fetal Toxicology. New York: Marcel Dekker; 1994:33-48.
4. Nulman I, Gladstone J, O'Hayon B, Koren G. The effects of alcohol on the fetal brain. In: Slikker W, Chan LW, eds. Handbook of Developmental Neurotoxicology. San Diego: Academic Press; 1998;567-86.
5. Russell M, Martier SS, Sokol RJ, et al. Detecting risk drinking during pregnancy: a comparison of four screening questionnaires. Am J Public Health 1996;86:1435-9
6. Stoler JM, Huntington KS, Peterson CM, et al. The prenatal detection of significant alcohol exposure with maternal blood markers. J Pediatr 1998;133:346-52.
7. Bernhardt TG, Cannistraro PA, Bird DA, et al. Purification of fatty acid ethyl esters by solid-phase extraction and HPLC. J Chromatogr B 1996;675:189-96.
8. Bearer CF, Gould S, Emerson R, et al. Fetal Alcohol Syndrome and Fatty Acid Ethyl Esters. Pediatr Res 1992;31:492-5.
9. Laposata EA, Lange LG. Presence of nonoxidative ethanol metabolism in human organs commonly damaged by ethanol abuse. Science 1986;231:497-9.
10. Laposata M, Szczepiorkowski M, Brown JE. Fatty Acid Ethyl Esters: Nonoxidative Metabolites of Ethanol. Prostaglandins, Leukot Essent Fatty Acids 1995;52:87-91.
11. Bearer CF, Moore C, Salvatore AE, et al. Meconium FAEE: Development of a biologic marker. Alcohol Clin Exp Res 1998;22: 103 A.
12. Ostrea EM Jr., Brady MG, Parks PM, et al. Drug screening of meconium in infants of drug-dependent mothers; an alternative to urine testing. J Pediatr 1989;115:474-7.
13. Klein J, Koren G. Testing for Drugs of Abuse in the Pediatric Population. In: Mieczkowski T, ed. Drug Testing Methods: Assessment and Evaluation. Boca Raton, FL: CRC Press, 1999:161-77.
14. Gladstone J, Levy M, Nulman I, Koren G. Characteristics of pregnant women who engage in binge alcohol consumption. Can Med Assoc J 1997;15:156, 789-94.